Worldwide Who's Who
About World Wide Who's Who    |    Who We Are    |    Member Benefits    |    FAQ    |    Contact Us
Worldwide Who's Who Home »
Print this news Printer Friendly     Email this news Email It



Narayan C. Chaudhuri, Ph.D., Inducted into Worldwide Who's Who for Excellence in Research and Development
Narayan C. Chaudhuri strives to make his mark on the oncology segment of pharmaceuticals
x-small text small text medium text large text



Narayan C. Chaudhuri, Ph.D.
    CAMBRIDGE, MA, March 15, 2013 /Worldwide Who's Who/ -- Narayan C. Chaudhuri, Ph.D., Senior Technical Support and cGMP Mfg Consultant to the Pharmaceutical Operations Division of Millennium - The Takeda Oncology Company, has been recognized by Worldwide Who's Who for showing dedication, leadership and excellence in the area of pharmaceutical development and commercial manufacturing of novel oncology drugs.

At Millennium - The Takeda Oncology Company, Dr. Chaudhuri is focused on the development and commercialization of proprietary small and large molecule drugs that have potential for treating cancer. Dr. Chaudhuri is highly equipped to provide leadership in the chemical synthesis, pharmaceutical development and commercialization of novel therapeutics for the treatment of various life-threatening and debilitating diseases.

Dr. Chaudhuri has accrued extensive experience in the pharmaceutical and biotechnology fields, and holds a strong record of publications in international scientific journals and patent literature. He has contributed to more than 15 different publications, most notably in the Journal of the American Chemical Society, Organic Process Research and Development, and Tetrahedron Letters. Dr. Chaudhuri hopes to make strides in the oncology sector of the pharmaceutical development that impacts the lives of people around the globe.

Prior to joining Millennium - The Takeda Oncology Company in 2012, Dr. Chaudhuri served in a variety of leadership roles such as QMS, CMC Tech Support and cGMP Manufacturing at Aveo Oncology, Inc. (2012-2012); Senior Compliance Specialist of Commercial cGMP and Bulk Quality Operations at Genzyme Corporation - A Sanofi Company (2011-2012); Organic Process Chemist at PolyOrg, Inc. (2011-2012); Associate Director of API Sourcing, CMC Management and cGMP Manufacturing at Sirtris Pharmaceuticals, Inc. - A GSK Company (2008-2010); Senior Manager of CMC, Chemical Development and cGMP Manufacturing at Epix Pharmaceuticals, Inc. (2007-2008); Principal Scientist of API Chemical Process R&D, Scale-up and Manufacturing at Idenix Pharmaceuticals, Inc. (2002-2007); Scientist/ Senior Scientist of API Chemical Process R&D, Scale-up and cGMP Manufacturing at Pharm-Eco - A Johnson Matthey Company (1997-2002); and Process Development Scientist at Hybridon, Inc. (1996-1997). Over the years he has led many high-performing scientific and cross-functional teams to success, while ensuring the on-time delivery of products and services. Along with managing complex projects in active pharmaceutical ingredients development and cGMP manufacture, he aligns corporate guidelines for delivering results and meeting business goals. Dr. Chaudhuri is committed to conceiving, designing and driving safe and robust processes to successful completion.

Dr. Chaudhuri has earned recognition as an expert in the chemical and pharmaceutical development of a variety of small and large molecule drugs for the treatment of cancer, major depressive disorder, Alzheimer's disease, obesity, PAH, COPD, IBS, HIV, HBV, and several metabolic and rare diseases. He developed novel methodologies for the synthesis of a number of small and large molecule drugs, including novel oligodeoxyribonucleotides and biologics, a specialization he earned through many years working within the biotech and pharmaceutical industry.

Dr. Chaudhuri is aided by a solid educational background. A Ph.D. graduate in synthetic organic chemistry from the Indian Institute of Technology Kanpur, he holds post-doctoral training in organic and bio-organic chemistry from the University of Rochester, NY and from the University of Illinois, Chicago for which he majored in solid-phase chemical synthesis of DNA, macromolecular recognition studies of nucleic acids and proteins, and structure-activity studies for anti-viral drug synthesis and development. Additionally, he is a designated Six Sigma Green Belt and an RAC offering expertise in quality engineering, SPC, FMEA, FDA/ICH/USP/EP/JP drug regulations, and CMO/CRO management.

For more information about Millennium - The Takeda Oncology Company, please visit http://www.millennium.com

About Worldwide Who's Who
With over 500,000 members representing every major industry, Worldwide Who's Who is a powerful networking resource that enables professionals to outshine their competition, in part through effective branding and marketing. Worldwide Who's Who employs similar public relations techniques to those utilized by Fortune 500 companies, making them cost-effective for members who seek to take advantage of its career enhancement and business advancement services.

Worldwide Who's Who membership provides individuals with a valuable third-party endorsement of their accomplishments, and gives them the tools needed to brand themselves and their businesses effectively. In addition to publishing biographies in print and electronic form, it offers an online networking platform where members can establish new professional relationships.

For more information, please visit http://www.worldwidewhoswho.com.

Contact:
Ellen Campbell
Director, Media Relations
mediarelations@wwregistry.com

# # #

Read more press releases by Worldwide Who's Who:

Press Release Contact Information:
Ellen Campbell
Worldwide Who's Who

Director, Public Relations
498 RXR Plaza,
Uniondale, NY
USA 11556
Voice: 516-833-8440 x1422
E-Mail: Email Worldwide Who's Who
Website: Visit the Worldwide Who's Who Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Worldwide Who's Who disclaims any content contained in this press release. Please see the complete Worldwide Who's Who Terms of Service for more information.